Plus Therapeutics (PSTV) Current Assets (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Current Assets data on file, last reported at $18.0 million in Q1 2026.

• Current Assets for Q1 2026 came in at $18.0 million, up 65.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.0 million (up 65.88% YoY), and the FY2025 annual result was $15.2 million, up 188.46% from the prior year.
• Current Assets advanced to $18.0 million in Q1 2026 per PSTV's latest filing, from $15.2 million in the prior quarter.
• Over five years, Current Assets peaked at $22.1 million in Q1 2022 and troughed at $4.2 million in Q1 2024.
• A 5-year average of $13.3 million and a median of $12.4 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets slumped 69.09% in 2024, then surged 227.85% in 2025.
• A 5-year view of Current Assets shows it stood at $21.8 million in 2022, then slumped by 54.93% to $9.8 million in 2023, then tumbled by 46.52% to $5.3 million in 2024, then surged by 188.46% to $15.2 million in 2025, then advanced by 18.84% to $18.0 million in 2026.
• Business Quant data shows PSTV's Current Assets at $18.0 million in Q1 2026, $15.2 million in Q4 2025, and $17.6 million in Q3 2025.